Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Entrepreneurship raises your risk of obesity, but small changes to your diet can have similar affects to new weight-loss ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Ozempic users are reporting unexpected hair loss, potentially linked to rapid weight loss and nutrient deficiencies, raising questions about the broader side effects of semaglutide medications.

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...